patients ' ESA response index and the division of responses into quintiles. This avoided inclusion of transiently hyporesponsive patients based on conditions not immediately apparent to the clinician. Our own experience suggests that a period of 6 months is needed to detect hyporesponsiveness in about 15 % of the hemodialysis population, who remain hyporesponsive for that duration. Th eir dose of ESA is markedly higher than that of sensitive patients, but because of the constraints of the ' target ' range, the same mean Hb is attained. Th e importance of detecting this subset resides in the economic cost of ESA therapy ( Figure 1 ) and in opportunities to avoid harm from " excessive " ESA dosing to reach the desired Hb target.
As important as economics is, the issue of risk versus benefit when higher Hb levels are targeted may be more important. If the findings of an association between the relative abundance of oncostatin M fragments and poor response, and between cysteine / histidine-rich 1 and good response, can be confi rmed in larger cohorts of patients, it may allow us to actually conduct the randomized controlled trials necessary to fi nd the best strategy for managing such poorly responsive patients. Certainly, this strategy cannot be to increase the ESA dose until the same Hb level is reached in poor as in better responders -that is, equivalent Hb attainment in all quartiles or quintiles of dose. Th e ability to periodically determine the responsiveness of the patient can only help refi ne the use and prevent the misuse of ESAs.
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The authors declared no competing interests. Chronic kidney disease (CKD) strongly increases patient risk for cardiovascular morbidity and mortality. Th is striking difference in cardiovascular risk between CKD patients and the general population is not attributable only to increased exposure to the traditional Framingham Study risk factors but in addition depends on a number of so-called ' novel, ' uremiarelated risk factors, among which miner-alization of blood vessels (vascular calcifi cation, an ectopic mineralization) takes a prominent position. 1 Numerous epidemiologic studies have found that vascular calcifi cation in CKD patients contributes to the increased cardiovascular risk in this population, and that hyperphosphatemia and hypercalcemic episodes are associated with the development of uremia-related vascular calcification. The intimate link between disturbances of mineral metabolism inherent to impaired renal function and the development of both renal osteodystrophy and vascular calcifi cation is now broadly captured under the term ' chronic kidney diseasemineral and bone disorder. ' 2
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Prevention of vascular calcification: is pyrophosphate therapy a solution ?
Veerle P. Persy 1 and Marc D. McKee 2 , 3
Pyrophosphate, a ubiquitous small-molecule inhibitor of mineralization abundantly present in the extracellular environment, binds to calcium and mineral surfaces to inhibit crystal growth. O ' Neill and colleagues show in uremic rats that systemic administration of pyrophosphate prevents or reduces uremia-related vascular calcification, without overt negative consequences for bone and without calcium pyrophosphate deposition disease. These findings prompt further research into the potential of pyrophosphate as treatment for vascular calcification in chronic kidney disease patients.
From a mechanistic point of view, vascular calcification emerges either as a direct mineralization of vascular extracellular matrix, as seen in medial elastic lamellae in the absence of inhibitory matrix Gla protein (MGP), or as a complex, cell-regulated process. In the latter case, disturbances in mineral metabolism attributable to renal function impairment trigger cellular transdiff erentiation of vascular smooth muscle cells into chondro-/ osteoblast-like cells, which produce matrix vesicles and other mediators of mineralization, including transcription factors and growth factors (such as Runx2 / Cbfa1, Msx2, Osterix, Sox9, and BMP2) normally associated only with skeletal and dental cells, as well as downstream, oftensecreted molecular determinants of mineralization (such as alkaline phosphatase, osteopontin, osteocalcin, bone sialoprotein, and MGP). The presence of cells capable of regulating mineralization in a uremic milieu -where calcium and phosphate, the ions necessary for mineral formation, are abundant, and a number of circulating and local mineralization inhibitors, such as MGP, fetuin-A, and pyrophosphate, are decreased -clearly sets the stage for the development of vascular calcifi cation.
O ' Neill and colleagues 3 (this issue) report that administration of the mineralization inhibitor pyrophosphate to uremic rats prevents or reduces the development of ectopic calcifi cation in blood vessels, without overtly aff ecting skeletal mineralization and without calcium pyrophosphate deposition disease in joints. In rats made uremic by administration of an adenine-rich diet, intraperitoneal administration of pyrophosphate (which is rapidly hydrolyzed if given orally) decreased the extent of calcium (mineral) deposition in calcifi ed vessels, but not the incidence of vascular calcifi cation. When calcitriol was used to induce vascular calcifi cation in uremic rats, pyrophosphate administration diminished both the incidence and the severity of vascular calcifi cation. Th ese fi ndings confi rm the importance of the phosphate -pyrophosphate ratio in the development of vascular calcifi cation and hint at a promising new pyrophosphate treatment approach for uremic CKD patients (or for any other patient group prone to ectopic mineralization, for that matter) disposed to vascular calcifi cation.
Whereas MGP ' s central, non-redundant role as a locally produced inhibitor of extracellular matrix mineralization in medial arterial calcification has been determined in mice, 4 other types of vascular calcifi cation are seemingly highly complex, involving a plethora of determinants acting at both the cellular and the extracellular level. Th ese typically involve infl ammation, cell necrosis with necrotic debris, apoptotic vesicles, matrix vesicles, lipid accumulation, and a reprogramming of vascular smooth muscle cells into the chondro-/ osteogenic pathway, resulting in the appearance of mineralized-tissue gene expression profi les in calcifi ed vessels. Once a calcifi cation focus is nucleated, further mineral deposition within it can be regulated by factors and secreted proteins that have been most extensively examined in studies on bone. Most prominent among these studies is work repeatedly describing upregulation of osteopontin (OPN) at these sites, where it colocalizes with mineral in the vessel wall and is thought to act as a reactionary molecule limiting further ectopic mineralization. Mice lacking both MGP and OPN show accelerated death by vascular rupture and increased deposition of vascular mineral as compared with mice defi cient in MGP alone. 4 While pyrophosphate ' s inhibitory eff ects on mineralization have long been known, as has the fact that these eff ects can be removed by degradation of pyrophosphate by the enzyme alkaline phosphatase, only in recent years has an understanding been achieved of how pyrophosphate is handled by cells to infl uence the phosphate -pyrophosphate ratio. In studies using primarily transgenic mice, a better understanding has now emerged of how pyrophosphate is transported extracellularly across the plasma membrane by the transporter ANK, or generated from nucleotides outside the cell at the level of the plasma membrane by ENPP1, then to be degraded by plasma membrane-resident tissuenonspecific alkaline phosphatase (TNAP). 5 Such processing of substrate pyrophosphate by TNAP simultaneously removes inhibitory pyrophosphate while generating two phosphate ions -both of which tip the phosphate -pyrophosphate ratio in favor of mineralization.
Bisphosphonates -nonhydrolyzable analogs of pyrophosphate widely used for the treatment of osteoporosis because of their toxicity to bone-resorbing osteoclastshave been reported to prevent vascular calcification in both experimental and clinical studies. 6, 7 At higher doses, bisphosphonates -like pyrophosphate -physicochemically inhibit mineral deposition, but their therapeutic use depends on inhibition of osteoclast-mediated bone resorption that occurs at low doses that do not interfere with the mineralization process.
Th e clinical usefulness of bisphosphonates to treat vascular calcification is limited, however, because the high doses that would be required to inhibit calcification in turn would adversely affect skeletal biology, and because bisphosphonates are eliminated from the body by renal clearance. Th us, most nephrologists would refrain from giving bisphosphonates to their CKD patients in view of the clearance problems and long halflife of these products on the one hand, and also because of the danger of inducing adynamic bone disease by oversuppression of bone turnover. Indeed, adynamic bone disease is associated with an increased risk for vascular calcifi cation, probably because adynamic bone cannot buff er excess calcium and phosphate in cases of hyperphosphatemia or hypercalcemic episodes. 8 Although O ' Neill and colleagues 3 did not observe any eff ect of pyrophosphate on certain commonly measured bone histology parameters, the potential adverse eff ects of pyrophosphate administration on bone need to be investigated more closely. Th e follow-up in this experimental study was limited to 4 weeks, and bone metabolism in rats and humans shows important diff erences, such as different growth and metabolic parameters that include a larger restoration capacity and buff er capacity for dealing with fl uctuations in calcium and phosphorus load in growing bone. Other characteristics of bone, such as mineral quantity and quality and its biomechanical properties, need to be assessed aft er pyrophosphate treatment. Th e lack of overt changes in some bone mineralization measurements is thought to be attributable to the abundant TNAP enzyme expressed by bone cells, which in cleaving pyrophosphate would limit the inhibitory eff ect of pyrophosphate on bone mineralization. Lesser production of TNAP by cells in the vessel wall, together with high local levels of circulating pyrophosphate arising from the systemic administration route and diff using into the vessel wall, may tip the local phosphate -pyrophosphate balance toward inhibition of mineral deposition ( Figure 1 ). Future studies on pyrophosphate treatment will require careful examination of pyrophosphate-handling gene expression (for example, ANK, ENPP1, and TNAP) in aff ected tissues, the eff ects of dosing and administration route, and of intermittent pyrophosphate treatment, always with attention being given to eff ects on bone mineralization and the possibility of calcium pyrophosphate deposition disease in joints.
Th is study -like all experimental studies on uremia-related vascular calcifi cation -inherently suffers from the limitations of the available animal models themselves. Feeding animals an adenine-rich diet reproducibly induces renal function impairment, but the fraction of animals in which vascular calcifi cation occurs is variable, even when the animals are maintained on a calcificationpromoting, low-protein diet. Although this variable incidence was circumvented experimentally by administration of supraphysiologic doses of calcitriol to induce consistent vascular calcifi cation, this animal model of calcifi cation may be too strong an induction model, and less representative of the situation in humans.
Pyrophosphate is a very short-lived molecule, with a half-life in rats of slightly more than 30 minutes, although the authors used various means to prolong the adsorption of pyrophosphate aft er peritoneal injection. Thus, it is as yet unclear whether this molecule is a suitable long-term treatment option for vascular calcification in humans. More research is needed to investigate the relationship between the short systemic half-life of this molecule and its eff ects on the local pyrophosphate concentration in tissue, particularly in the vascular wall. If the tissue half-life of this molecule surpasses its systemic half-life by multiple orders of magnitude, long-term administration of pyrophosphate may cause this molecule to accumulate extracellularly in the tissue, potentially leading to longterm consequences for bone formation and mineralization.
Th e short half-life of pyrophosphate also triggers the question of the optimal route for administration. Whereas it may be feasible to expose peritoneal dialysis patients continuously to pyrophosphate, for dialysis patients or CKD patients not yet on dialysis, frequent and continuous exposure to pyrophosphate seems less feasible.
Vascular calcifi cation is now well established as a surrogate marker of cardiovascular risk in CKD patients. However, it remains to be determined whether inhibition of vascular calcifi cation is suffi cient to halt the multifactorial pathogenetic mechanisms that lead to arterial stiff ening, calcifi cation, and increased cardiovascular mortality risk. And, although a number of interventions have been shown in either animals or patients to inhibit the development of vascular calcifi cation, there is a paucity of evidence that interventions can reverse established calcifi cations. When renal function is restored by transplantation, this seems to halt the progression of calcifi cation but does not reverse the calcifi cation pro cess, 9 although experimental studies yield confl icting results. Taking into account the highly insoluble nature of the depo sited bioapatite, regression of vascular calcifi cation likely would have to invoke an active, cell-regulated resorption pro cess that parallels mechanisms of bone resorption by lowering extracellular pH. 10 It thus seems unlikely that pyrophosphate would have a role in any vascular mineral regression process of established calci fi cations, especially when pyrophosphate additionally slows mineral dissolution.
In summary, O ' Neill and colleagues 3 present convincing experimental evidence that systemic administration of pyrophosphate to uremic rats inhibits the development of uremia-related vascular calcifi cation, without apparent adverse eff ects on bone mineralization.
